RESTORE clinical trial of STR001 : Strekin completes patient enrollment

RESTORE clinical trial of STR001 : Swiss biopharma company Strekin has wrapped up patient enrollment in a phase 3 study, called RESTORE, for evaluating its small molecule STR001 in patients after a sudden sensorineural hearing loss (SSNHL) event.

The late-stage trial is a global, randomized, placebo-controlled study, which will feature 165 patients at nearly 25 clinical centers in five European countries.

The RESTORE clinical trial will study the ability of STR001 administered through intratympanic injection with and without a three-month oral follow-up with the investigational tablets to restore hearing in SSNHL.

According to Strekin, STR001 has been very well tolerated and expects to release topline results from the RESTORE clinical trial in early 2020.

Strekin completes patient enrollment for RESTORE phase 3 clinical trial of STR001. Image courtesy of ponsulak at FreeDigitalPhotos.net.

Commenting on the RESTORE clinical trial of STR001, Alexander Bausch – CEO of Strekin, said: “We are pleased to have completed patient enrollment in the Phase 3 RESTORE clinical trial which is designed to evaluate the ability of STR001 activity to reverse hearing loss following a SSNHL event.

“The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered severe hearing loss that may lead to a debilitating life-long handicap. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL in the EU, may enable STR001 to become the first approved treatment for SSNHL patients.”

STR001 is an agonist of the Peroxisome Proliferator Activated Receptor gamma (PPAR-g), which has various beneficial roles in inflammation, cellular metabolism, and oxidative stress. Preclinical data published by the Swiss biopharma company and its collaborators showed that the PPAR-g agonist protects hearing in animal models effectively by preventing oxidative stress and by bringing down activation levels of inflammatory signaling in the cochlea.

For more updates on the RESTORE clinical trial of STR001 and other clinical trial news, keep following Pharma News Daily.

Related posts

• Gilead Sciences licenses three preclinical antiviral programs from Novartis (0)
• Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics (0)
• Sensorion gets FDA nod for SENS-401 trial for inner ear condition (0)
• Pfizer wraps up $810m acquisition of Swiss biotech company Therachon (0)
• Merck to invest €150m to expand Aubonne biotech manufacturing site (0)
• Orphan Technologies begins OT-58 phase 1/2 trial in classical homocystinuria (0)
• Novartis to acquire US biopharma company Endocyte for $2.1bn (0)
• Roivant launches Respivant Sciences to develop drugs for respiratory diseases (0)
• Urovant licenses overactive bladder gene therapy hMaxi-K from Ion Channel (0)
• Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients (0)

The post RESTORE clinical trial of STR001 : Strekin completes patient enrollment appeared first on PharmaNewsDaily.com.